St. Jude wins European approval for cardiac ablation system
June 17, 2010 by MedCity News
St. Jude Medical Inc. lands European regulatory approval for a cardiac ablation system used to correct arrhythmias.
St. Jude Medical Inc. (NYSE:STJ) received European regulatory approval for a cardiac ablation system used in procedures to destroy diseased tissue in patients with abnormal heart rhythms.
Receiving the CE Mark means that St. Jude may beginning marketing and selling its EnSite Contact Technology platform in the Eurpean Union. The system has not been cleared for U.S. sales.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
Navigation
NEWS
FDA approves Bausch + Lomb's eye implant
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
Claret Medical's filter thwarts debris headed for the brain in TAVI patients, study shows
California medical device maker Claret Medical's embolic protection technology captures debris...
Report: Galt Medical's Texas plant closure means 139 layoffs
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...
FLASH: Medtronic's Q4, 2013 profits slide
Medtronic's fiscal 4th-quarter and 2013 profits slide on low-single-digit revenue growth, but the...
Wound Management Technologies settles tax liability
Wound Management Technologies strikes a deal with the IRS to settle payroll tax liabilities and...
